.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Progressive keratoconus is driven by progressive corneal biomechanical weakening and can lead to increasing irregular astigmatism and visual loss. A prospective randomized controlled trial evaluated corneal collagen cross-linking in 100 eyes with progressive disease. The treated eyes were compared with control eyes over three years using maximum keratometry, visual acuity, refraction and corneal measurements. Cross-linking stabilised corneal curvature relative to the untreated control group and was associated with visual improvement in several measures. The study provides important evidence that CXL is not simply a refractive procedure—it aims to alter the trajectory of the disease by strengthening the corneal stroma. For HCPs, the critical issue is identifying progression early enough for treatment to preserve corneal shape and visual potential. CXL should be integrated with topography/tomography-based monitoring and appropriate management of allergic eye rubbing and ocular surface disease. The trial directly supports AIOC's emphasis on CXL protocols and management of progressive keratoconus.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Progressive keratoconus is driven by progressive corneal biomechanical weakening and can lead to increasing irregular astigmatism and visual loss. A prospective randomized controlled trial evaluated corneal collagen cross-linking in 100 eyes with progressive disease. The treated eyes were compared with control eyes over three years using maximum keratometry, visual acuity, refraction and corneal measurements. Cross-linking stabilised corneal curvature relative to the untreated control group and was associated with visual improvement in several measures. The study provides important evidence that CXL is not simply a refractive procedure—it aims to alter the trajectory of the disease by strengthening the corneal stroma. For HCPs, the critical issue is identifying progression early enough for treatment to preserve corneal shape and visual potential. CXL should be integrated with topography/tomography-based monitoring and appropriate management of allergic eye rubbing and ocular surface disease. The trial directly supports AIOC's emphasis on CXL protocols and management of progressive keratoconus.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
